Open AccessThe effectiveness of psychological support with the use of hepato-immunoprotectors as predictors in drug therapy of tuberculosis
Author(s) -
D. Yu. Belousov,
М. А. Алыменко,
А. Л. Коваленко,
Евгений Петрович Павленко,
Е. В. Таликова
Publication year - 2021
Publication title -
antibiotiki i himioterapiâ
Language(s) - English
Resource type - Journals
ISSN - 0235-2990
DOI - 10.37489/0235-2990-2021-66-5-6-40-47
Subject(s) - medicine , tuberculosis , pulmonary tuberculosis , drug , pharmacotherapy , drug resistance , medical prescription , directly observed therapy , mycobacterium tuberculosis , pharmacology , pathology , microbiology and biotechnology , biology
The aim of the study was to evaluate the effectiveness of psychological (adherence to treatment) and accompanying drug therapy depending on the form of pulmonary tuberculosis. The results of complex therapy of 326 patients with various forms of pulmonary tuberculosis are considered. All patients received etiotropic treatment, taking into account the sensitivity of the pathogen to anti-tuberculosis drugs, as well as support therapy, including psychological support and, if indicated, hepatoprotective therapy with Remaxol. When analyzing the dependence of the psychoemotional state of patients on the form of the tuberculous process in the lungs, it was noted that high adherence to therapy was observed in one third of patients in all groups (DTL — 26.1%, ITL — 28.6%, FCTL — 32.8% and ATL — 31.8%, respectively, P >0.05). The results obtained may be associated with a high level of resistance of mycobacterium tuberculosis excreted from pa tients: out of 232 patients with low adherence to treatment (NUP and UUP), 97 (36.2%) showed drug resistance of the pathogen to two or more etiotropic drugs, which, in turn, caused prescription of reserve drugs. Thus, the determination of the level of adherence to treatment is justified and is aimed at correcting the psychological support of patients with pulmonary tuberculosis, which makes it possible to increase the effectiveness of therapy in these patients. The appointment of the latter in a number of patients led to the development of hepatotoxic reactions, which served as the basis for the inclusion in the therapy regimens of the accompaniment of Remaxol (intravenous drip of 400 ml, course No. 5–7). Pronounced hepatoprotective (improved transaminase parameters) and insignificant immunoprotective (positive dynamics of the cytokine profile) effects were noted during treatment. The noted changes in the immunogram can be associated with the proven antioxidant and membrane stabilizing effect of succinic acid, which is part of Remaxol. These changes require further research.